GlassScriptPhysician profile
Jennifer Bartley
NPI 1659852556
$2,202.15
in general payments reported to CMS, 2019-2025
19 companies · $611 in 2025
The $611 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
See the full distribution for Psychiatric/Mental Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $288 · 2022: $262 · 2023: $342 · 2024: $699 · 2025: $611.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,652.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $446.92 | 2021-2025 | Spravato, Invega Sustenna |
| Otsuka America Pharmaceutical, INC. | $340.97 | 2021-2024 | Rexulti |
| Axsome Therapeutics, INC. | $306.44 | 2023-2025 | Auvelity |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $204.78 | 2021-2025 | Caplyta |
| Abbvie INC. | $178.02 | 2021-2024 | |
| Vanda Pharmaceuticals INC. | $143.33 | 2024-2025 | Fanapt |
| Alkermes, INC. | $122.31 | 2022-2025 | Lybalvi, Aristada |
| Takeda Pharmaceuticals U.S.A., INC. | $80.87 | 2021-2025 | Ninlaro, Vpriv, Trintellix |
| Lundbeck LLC | $75.60 | 2023-2025 | Abilify Maintena, Rexulti |
| Indivior INC. | $61.68 | 2024-2025 | Sublocade |
| Biogen, INC. | $55.82 | 2025 | Zurzuvae |
| Acadia Pharmaceuticals INC | $52.35 | 2021-2024 | Nuplazid |
| Genentech USA, INC. | $40.90 | 2024 | Tecentriq, Phesgo, Tecentriq Hybreza |
| Ironshore Pharmaceuticals INC. | $19.72 | 2024 | |
| Tris Pharma INC | $17.30 | 2024 | Dyanavel Xr |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $16.79 | 2025 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $14.96 | 2023 | Uzedy |
| Supernus Pharmaceuticals, INC. | $14.47 | 2023 | Qelbree |
| Corium, LLC | $8.92 | 2025 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Bartley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.